AC Immune SA
Business
AC Immune SA is a clinical-stage biopharmaceutical company advancing Precision Medicine approaches for neurodegenerative diseases. It develops therapeutics and diagnostics, including active immunotherapies, monoclonal antibodies, small-molecule Morphomers, and PET imaging tracers targeting Abeta, Tau, alpha-synuclein, TDP-43 and NLRP3‑ASC. Its operations revolve around two proprietary platforms, SupraAntigen and Morphomer, and a pipeline organized into therapeutic and diagnostic programs with collaboration and licensing arrangements. The company advances clinical development primarily in the U.S. and select European markets while partnering with global pharmaceutical companies and contract manufacturing organizations.
Summary from filing dated 2025-03-13
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-70.45M |
| Total assets | $154.25M |
| Total liabilities | $109.37M |
| Stockholders' equity | — |
| Operating cash flow | — |